Cognition Therapeutics, Inc 已成功完成与美国食品药品监督管理局(FDA)就其在研药物Zervimesine (CT1812)用于治疗路易体痴呆伴精神病症适应症所举行的会议。
Cognition Therapeutics, Inc 已成功完成与美国食品药品监督管理局(FDA)就其在研药物Zervimesine (CT1812)用于治疗路易体痴呆伴精神病症适应症所举行的会议。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.